TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16009165
Drug: Cetrorelix acetate
Normalized name: Cetrorelix Acetate
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetrorelix acetate (3 mg SC)
Study: 16009165
Drug: Ganirelix acetate
Normalized name: Ganirelix Acetate
DrugBank: Ganirelix (DB06785)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganirelix acetate (0.25 mg SC daily)
Study: 555598
Drug: Theolair SR
Normalized name: Theolair SR 250mg Extended-Release Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theolair SR (10 mg/kg)
Study: 555598
Drug: Theo-Dur (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theo-Dur (10 mg/kg)
Study: 30653957
Drug: Netarsudil 0.02%
Normalized name: NETARSUDIL 0.02% OPH SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netarsudil 0.02% twice a day (b.i.d.)
Study: 28732822
Drug: Beta-lactam monotherapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-lactam monotherapy continued
Study: 11840581
Drug: Edrophonium 1
Normalized name: edrophonium 10 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 1 mg/kg and atropine 0.01 mg/kg
Study: 7625120
Drug: 160 RIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 RIA antigen unit dose
Study: 1978161
Drug: daily injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily injections of growth hormone (rhGH) at 30 IU/m2 per week
Study: 21709202
Drug: ASA404 (vadimezan)
Normalized name: Vadimézan
DrugBank: Vadimezan (DB06235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA404 (vadimezan) 1800 mg/m2, given intravenously once every 3 weeks for six cycles followed by maintenance ASA404
Study: 21709202
Drug: ASA404 (vadimezan)
Normalized name: Vadimézan
DrugBank: Vadimezan (DB06235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA404 (vadimezan) 1800 mg/m2
Study: 12527976
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g glucose (PLAC)
Study: 12527976
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g glucose (LOW)
Study: 12527976
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g glucose (MED)
Study: 12527976
Drug: 200 g
Normalized name: PEG-200 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 g glucose (HIGH)
Study: 10583700
Drug: Haloperidol 30
Normalized name: Haloperidol 300 microgram/mL oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 30 mg/day plus Piracetam 3200 mg/day
Study: 10583700
Drug: Haloperidol 30
Normalized name: Haloperidol 300 microgram/mL oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 30 mg/day plus Placebo
Study: 1988321
Drug: Ginger (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger (1 g daily for 4 days)
Study: 6874891
Drug: Dexamethasone phosphate
Normalized name: Dexamethasone Phosphate
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone phosphate (5 mg each) at 12-h intervals for 4 injections
Study: 26657041
Drug: e‐Learning +
Approvals — FDA: no, EMA: no, PMDA: no
Description: e‐Learning + Workshop (e‐L + W)
Study: 26657041
Drug: e‐Learning (e‐L)
Approvals — FDA: no, EMA: no, PMDA: no
Description: e‐Learning (e‐L)
Study: 10591680
Drug: Raloxifene hydrochloride
Normalized name: Raloxifene Hydrochloride
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raloxifene hydrochloride 60 mg/d
Study: 10591680
Drug: Raloxifene hydrochloride
Normalized name: Raloxifene Hydrochloride
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raloxifene hydrochloride 150 mg/d
Study: 10591680
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (CEEs) 0.625 mg/d
Study: 1661506
Drug: Cavinton (additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cavinton (additional to conventional therapy)
Study: 6818707
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate 2 mg/ml
Study: 6818707
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate 10 mg/ml
Study: 6818707
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate 20 mg/ml
Study: 6818707
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate 40 mg/ml
Study: 27732083
Drug: Individualized acupuncture
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized acupuncture treatment (AT)
Study: 25055057
Drug: Fresh rose
Normalized name: TITANIUM DIOXIDE 5.6 g in 100 mL TOPICAL LOTION [COOLA Rosilliance Mineral Tinted Face Moisturizer SPF 30 Fresh Rose]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh rose flowers as an olfactory stimulant
Study: 10325836
Drug: PCA with
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA with piritramide 0.75 mg
Study: 10325836
Drug: PCA with
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA with piritramide 1.5 mg
Study: 1679316
Drug: Nizatidine 300
Normalized name: nizatidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine 300 mg daily
Study: 6848648
Drug: Alcohol (1.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (1.1 ml/kg)
Study: 11777833
Drug: Recombinant glycoprotein
Normalized name: Recombinant glycoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant glycoprotein (RGP) vaccines
Study: 20372089
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated varicella-zoster virus (VZV) vaccine, two doses 12 weeks apart
Study: 15916369
Drug: EHF‐IR therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: EHF‐IR therapy on biologically active points
Study: 15916369
Drug: EHF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: EHF therapy alone
Study: 12105828
Drug: Erythromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (250 mg intravenous bolus infusion, 20 minutes before endoscopy)
Study: 9545623
Drug: Standard hypocaloric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard hypocaloric diet + ephedrine (2 x 25 mg) + caffeine (2 x 200 mg)
Study: 9545623
Drug: Standard hypocaloric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard hypocaloric diet + ephedrine (2 x 25 mg) + caffeine (2 x 200 mg) + yohimbine (2 x 5 mg)
Study: 20919
Drug: Rimiterol 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimiterol 0.5% (second dose 2h after first)
Study: 20919
Drug: Rimiterol 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimiterol 0.5% (first dose)
Study: 26289742
Drug: Fluticasone propionate/salmeterol
Normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate/salmeterol (FP/SAL) 100/50 mcg
Study: 26289742
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 100 mcg
Study: 8036686
Drug: Diethylcarbamazine (DEC)
Normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diethylcarbamazine (DEC) treatment
Study: 17026651
Drug: Poria cocos
Normalized name: WOLFIPORIA COCOS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poria cocos (PoCo) applied in three concentrations in base cream DAC during the induction period of ICD.
Study: 10954340
Drug: Gastric lavage
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric lavage (10x200 ml)
Study: 9310272
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (PGE1) infusion (120 microg/day) for 7 consecutive days
Study: 3360973
Drug: 7432-S 25
Normalized name: (S)-2,5-Diaminopentanoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7432-S 25 mg
Study: 3360973
Drug: 7432-S 50
Normalized name: HYMETELLOSE (50 MPA.S)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7432-S 50 mg
Study: 3360973
Drug: 7432-S 100
Normalized name: ethylcellulose (100 MPA S)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7432-S 100 mg
Study: 3360973
Drug: 7432-S 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7432-S 200 mg
Study: 3360973
Drug: 7432-S 100
Normalized name: ethylcellulose (100 MPA S)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7432-S 100 mg twice daily for 2 weeks
Study: 3360973
Drug: 7432-S 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7432-S 200 mg twice daily for 1 week
Study: 3360973
Drug: 7432-S (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7432-S (all doses)
Study: 31106840
Drug: Pre-treatment with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment with antiplatelet drugs (acetylsalicylic acid 15 mg/kg, clopidogrel 11 mg/kg, ticagrelor 27 mg/kg, prasugrel 1.5 mg/kg)
Study: 31106840
Drug: Pre-treatment with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment with antiplatelet drugs
Study: 31106840
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antiplatelet treatment)
Study: 29753703
Drug: NGR-hTNF 0·8
Approvals — FDA: no, EMA: no, PMDA: no
Description: NGR-hTNF 0·8 μg/m2 intravenously plus best investigator choice (n=200)
Study: 29753703
Drug: NGR-hTNF 0·8
Approvals — FDA: no, EMA: no, PMDA: no
Description: NGR-hTNF 0·8 μg/m2 intravenously
Study: 28192892
Drug: Nefopam (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam (IV 120 mg continuous infusion for 48 hours)
Study: 28192892
Drug: Control (placebo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo, same infusion for 48 hours)
Study: 17119469
Drug: Antioxidant vitamins
Normalized name: antioxidant vitamins with minerals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant vitamins and minerals (120 mg vitamin C, 30 mg vitamin E, 6 mg beta-carotene, 100 microg selenium, 20 mg zinc)
Study: 7957149
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Atenolol and Scopolamine
Study: 2955007
Drug: Biperiden (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biperiden (intravenous administration)
Study: 31994405
Drug: Cycle ergometer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycle ergometer training group (10-minute session, twice a day)
Study: 29653208
Drug: Ixekizumab 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab 120 mg, then 80 mg subcutaneously once every 4 weeks
Study: 27470183
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate (GTN) patch applied for 24 hours after surgery
Study: 27470183
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch applied for 24 hours after surgery
Study: 20852375
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid capsule, 1 g 3 times a day for 2 months
Study: 18285430
Drug: Exercise intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exercise intervention (twice-weekly classes and once-weekly independent exercise for three months)
Study: 18285430
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (monitored monthly, management unchanged)
Study: 3088219
Drug: Cisplatin (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (120 mg/m2) plus Vindesine
Study: 3088219
Drug: Cisplatin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (60 mg/m2) plus Vindesine plus Mitomycin C
Study: 28786494
Drug: DBBM and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBBM and L‐PRF mixture (test)
Study: 27409478
Drug: Aflibercept or
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aflibercept or ranibizumab intravitreal injections
Study: 12814477
Drug: T-cell depleting
Normalized name: Virus Specific T-Cell
DrugBank: Virus Specific T-Cell (DB15735)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-cell depleting antibody induction
Study: 8855815
Drug: Estradiol 0.1
Normalized name: estradiol 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol 0.1 mg/day transdermally
Study: 1516394
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of furosemide following a single loading dose (LDCI)
Study: 1516394
Drug: Intermittent intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent intravenous administration of furosemide (IA)
Study: 3841410
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg pirenzepine
Study: 3841410
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg pirenzepine twice daily
Study: 3841410
Drug: 17.5 mg
Normalized name: acitretin 17.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17.5 mg benzilonium bromide twice daily
Study: 3841410
Drug: 35 mg
Normalized name: papain 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg benzilonium bromide twice daily
Study: 3841410
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg L-hyoscyamine twice daily
Study: 29923955
Drug: 1.5 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mL/kg lipid infusion (lipid group)
Study: 9345448
Drug: BRB‐N tests
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRB‐N tests administered every 60 days for 120 days
Study: 2264720
Drug: Cubital nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cubital nerve block with prilocaine (15 ml of 10 mg/ml)
Study: 30704414
Drug: Standard heart
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard heart failure therapy
Study: 19764439
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl analgesia (0.7 microg x kg(‐1) x hr(‐1) during operation, decreased to 0.5 microg x kg(‐1) x hr(‐1) next morning)
Study: 19764439
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia (0.4 microg x kg(‐1) x hr(‐1) fentanyl and 5 ml x hr(‐1) 1% mepivacaine during operation)
Study: 15061241
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (CE) (0.625 mg/day)
Study: 9551707
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg every morning for 2 weeks
Study: 9551707
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg every morning with cimetidine 300 mg four times a day for 2 weeks
Study: 2899586
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of netilmicin and metronidazole
Study: 25592008
Drug: Lactoferrin-fortified formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactoferrin-fortified formula (38 mg/100 g milk, iron 4 mg/100 g milk)
Study: 25592008
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no lactoferrin, iron 4 mg/100 g milk)
Study: 12698851
Drug: Broncholytics (basic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broncholytics (basic treatment)
Study: 30763468
Drug: Pulsed Signal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed Signal Therapy (PST)
Study: 27203797
Drug: N-methyl D-aspartate
Normalized name: N-methyl-D-glucamine
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-methyl D-aspartate (NMDA) receptor antagonists
Study: 22266741
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL of hyaluronic acid (HA)
Study: 10332444
Drug: Trazodone 50
Normalized name: traZODone 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone 50 mg at bedtime
Study: 30993684
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (n = 29) received two 75-min lessons on evaluating the credibility of online content.
Study: 17235334
Drug: rosiglitazone 8
Normalized name: rosiglitazone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone 8 mg/day for 6 months
Study: 12480424
Drug: Single-dose azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-dose azithromycin (20 mg/kg bodyweight, maximum individual dose 1 g; n=65)
Study: 12480424
Drug: 12.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg/kg erythromycin (maximum dose 500 mg; n=63)
Study: 9620115
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of a standard trivalent influenza vaccine
Study: 9620115
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of a standard trivalent influenza vaccine
Study: 347112
Drug: deanol acetamidobenzoate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: deanol acetamidobenzoate, 2.0 g/day for four weeks
Study: 21711059
Drug: Fostamatinib 100
Normalized name: fostamatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostamatinib 100 mg twice daily
Study: 19139013
Drug: Combined 13‐cis‐retinoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined 13‐cis‐retinoic acid daily, alpha‐IFN twice weekly, and alpha‐tocopherol daily for 1 year
Study: 15325237
Drug: Natural compounds
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural compounds collected from lactating women and their breastfeeding infants
Study: 3098825
Drug: Intramuscular route
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular route of FSH administration
Study: 3098825
Drug: Pulsatile subcutaneous
Normalized name: PULSATILLA PRATENSIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsatile subcutaneous route of FSH administration
Study: 23558840
Drug: Dexamethasone (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (IV 8 mg)
Study: 12114338
Drug: Tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 microg once daily via dry-powder inhaler
Study: 12114338
Drug: Salmeterol 50
Normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 50 microg bid via metered-dose inhaler
Study: 782144
Drug: Propranolol (Inderal)
Normalized name: propranolol Extended Release Oral Capsule [Inderal]
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol (Inderal) 160 mg/d
Study: 28034981
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen (IVA) 1000 mg
Study: 28034981
Drug: Oral acetaminophen
Normalized name: acetaminophen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acetaminophen (OA) 1000 mg
Study: 25595413
Drug: Thoracic spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic spinal manipulative therapy (SMT)
Study: 8197033
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg every 12 hours (C500)
Study: 8197033
Drug: Ciprofloxacin 750
Normalized name: ciprofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 750 mg every 12 hours (C750)
Study: 8197033
Drug: Nalidixic acid
Normalized name: Nalidixic Acid
DrugBank: Nalidixic acid (DB00779)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nalidixic acid 1 g every 6 hours (NA)
Study: 2884813
Drug: guanfacine 1-2
Normalized name: guanfacine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: guanfacine 1-2 mg
Study: 31202690
Drug: Ritonavir-boosted darunavir
Normalized name: Darunavir
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir-boosted darunavir 400 mg once daily
Study: 31202690
Drug: Ritonavir-boosted lopinavir
Normalized name: lopinavir / ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir-boosted lopinavir 800 mg plus 200 mg ritonavir
Study: 24928790
Drug: FP‐01.1 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP‐01.1 (150 μg/peptide dose group)
Study: 23705536
Drug: Daily patient-applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily patient-applied subgingival root brushing for 14 days
Study: 22256633
Drug: Moxibustion treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion treatment (3 cones on each point, applied to Neixiyan, Dubi, and Ashi points, once every two days, 3 times per week for 6 weeks)
Study: 22256633
Drug: Placebo moxibustion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo moxibustion treatment (placebo moxa sticker applied to the same points)
Study: 19822595
Drug: High-dose cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cysteine (81 mg/kg per day)
Study: 19822595
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose cysteine (45 mg/kg per day)
Study: 9644774
Drug: Continuous sequential
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous sequential regimen of 5 micrograms/day of estradiol and 5 mg/day of medrogestone from the 17th to the 28th day of the cycle (Group A)
Study: 9644774
Drug: Continuous administration
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous administration of 50 micrograms/day estradiol and 5 mg/day medrogestone (Group B)
Study: 8187428
Drug: 40, 80,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40, 80, 120, 160 or 200 mg rimexolone (Org 6216)
Study: 3556307
Drug: Irradiation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irradiation therapy
Study: 3556307
Drug: Combined chemo‐irradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined chemo‐irradiation therapy (Adriamycin/Cyclophosphamide)